DEFINITIVE CONTRACT
Active75A50126C00010
Department of Health and Human Services › Office of Assistant Secretary for Preparedness and Response › BARDA - ASPR / DAAPPO / BARDA DCMA
$96.1M
obligated · signed 6 days ago
THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOINJECTORS (AS A DRUG/DEVICE COMBINATION PRODUCT) TO TREAT ORGANOPHOSPHATE (OP) POISONING, INCLUDING NERVE AGENT
Performance timeline
Start
Sep 30, 2026
End
Dec 31, 2034
with all options
Loading status
Estimated start: Dec 31, 2033
KALEO, INC.
Contract 75A50126C00010
UEI
LBM4GLJNDK31
Parent Company
KALEO, INC.
Capabilities & Certifications
Headquarters Location
Congressional District: 01
Current Obligation
$96,058,494
Base + Exercised Options
$96,058,494
Total Ceiling Value
$340,910,795
Contract Type
COST PLUS FIXED FEE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Place of Performance
Congressional District: 01
Awarding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Solicitation procedures, competition exceptions, labor standards and account totals.